Loading clinical trials...

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01241591•Pfizer

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);
•Have plaque-type psoriasis covering at least 10% of total body surface area
•Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis

Exclusion Criteria

•Non-plaque or drug induced forms of psoriasis
•Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis
•Cannot discontinue phototherapy
•Any uncontrolled significant medical condition

Locations (122)

Centro de Investigaciones Dermatologicas

Buenos Aires, C1114aap, Argentina

Centro de Investigaciones Dermatologicas

Buenos Aires, Argentina

IMAI (Instituto Medico de Asistencia e Investigaciones)

Buenos Aires, Argentina

LKH Feldkirch Abteilung fuer Dermatologie und Venerologie

Feldkirch, Austria

LKH Innsbruck Universitaetsklinik fuer Dermatologie und Venerologie

Innsbruck, Austria

LKH Salzburg, Landesklinik fuer Dermatologie

Salzburg, Austria

Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel

Vienna, Austria

Cliniques universitaires Saint-Luc

Brussels, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

Department for skin and venerial diseases, Clinical Center University of Sarajevo

Sarajevo, Bosnia and Herzegovina

Key Dates

Start Date

November 1, 2010

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

December 26, 2018

Enrollment

1,101

ACTUAL participants

Conditions

Psoriasis

Interventions

CP 690,550 5 mg

DRUG

CP 690,550 10 mg

DRUG

Etanercept 50 mg

BIOLOGICAL

Placebo

OTHER

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments